Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy
Academic Article
Publication Date:
2017
abstract:
Background. The endocannabinoid system has been implicated in the pathogenesis of diabetic nephropathy (DN). We investigated the effect of combined therapy with AM6545, a 'peripherally' restricted cannabinoid receptor type 1 (CB1R) neutral antagonist, and AM1241, a cannabinoid receptor type 2 (CB2R) agonist, in experimental DN.
Iris type:
01.01 Articolo in rivista
Keywords:
albuminuria; CB2R agonist; CB1R antagonist; diabetic nephropathy; endocannabinoid system
List of contributors:
DI MARZO, Vincenzo
Published in: